Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection
Journal of Viral Hepatitis Aug 18, 2019
Read P, Gilliver R, Kearley J, et al. - In this observational cohort study, researchers assessed treatment adherence when receiving direct-acting antivirals (DAAs) in a highly marginalized population at the Kirketon Road Centre, which is a community-based public health facility in Sydney, Australia. According to the findings, overall adherence was 86%; 92% of patients missed one or more doses. In 38%, they reported at least 90% adherence during planned duration, but that grew to 66% as a result of therapy continuing past the planned length. They concluded that those with multiple markers of marginalization may derive benefit from adherence support. Completion of therapy can be improved by extending therapy beyond the planned length of time. There is a need for strategies to enhance follow-up, especially posttreatment.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries